Fundraising Fox

Nextcure

NASDAQ: NXTC

Beltsville, US · Founded 2015 · Delaware corporation · 8 known investors

nextcure.com ↗

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

Biotech

Founders & leadership

TM
Timothy MayerNamed on SEC filing
MR
Michael RichmanNamed on SEC filing
EV
Elaine V. JonesNamed on SEC filing
UG
Udayan GuhaNamed on SEC filing
AB
Anne BorgmanNamed on SEC filing
SP
Steven P. CobournNamed on SEC filing
SK
Sourav KunduNamed on SEC filing
EF
Ellen FeigalNamed on SEC filing
SW
Stephen WebsterNamed on SEC filing
JG
John G. HoustonNamed on SEC filing
KS
Kevin ShawNamed on SEC filing
CG
CAROLYN GREENNamed on SEC filing

Investors · 8

Canaan PartnersStamford · $500K – $20Mvia Tim Shannon · board
LAVHong Kong · $5M – $15M
Lilly Asia VenturesHong Kongvia Hongbo Lu · inferred
Pfizer Venture Investments$5M – $20M
Quan CapitalShanghai
Sofinnova VenturesMenlo Park · $100K – $15M
Taiho Ventures, LLCMenlo Park
OrbiMedreportedNew York · $1M – $75Mvia Chau Khuong · board

Reported raises · per SEC filings

Form D private placements

$129.9M disclosed across 3 rounds · 2015–2025

▶$21.5MraisedDec 2025 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Timothy MayerExecutive Officer
  • Michael RichmanExecutive Officer, Director
  • Elaine V. JonesDirector
  • Udayan GuhaExecutive Officer
  • Anne BorgmanDirector
  • Steven P. CobournExecutive Officer
  • David KabakoffDirector
  • Sourav KunduExecutive Officer
  • Ellen FeigalDirector
  • Stephen WebsterDirector
  • John G. HoustonDirector
  • Kevin ShawExecutive Officer
Offering amount
$21.5M
Amount sold
$21.5M
Finders' fees
$1.2M
Placement agents
H.C. Wainwright & Co., LLC
First sale
Nov 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$93.4MraisedNov 2018 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stella XuDirector
  • Michael RichmanExecutive Officer, Director
  • Michael YiDirector
  • Judith LiDirector
  • Chau Q. KhuongDirector
  • Kevin N. HellerExecutive Officer
  • David KabakoffDirector
  • Steven CobournExecutive Officer
  • Tim ShannonDirector
  • Elaine JonesDirector
Offering amount
$93.4M
Amount sold
$93.4M
First sale
Nov 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15MraisedJan 2016 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • CAROLYN GREENDirector
  • ASHER RUBINExecutive Officer
  • DAVID KABAKOFFDirector
  • TIM SHANNONDirector
  • MICHAEL RICHMANExecutive Officer, Director
  • JUDITH LIDirector
  • CHAU Q. KHUONGDirector
Offering amount
$67M
Amount sold
$15M
First sale
Dec 2015
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

H.C. Wainwright reiterates NextCure stock rating on merger news By Investing.cominvesting.com · Jul 2026NextCure backs Avere merger with $320 million financing | Grafagrafa.com · Jul 2026NextCure (NASDAQ: NXTC) sets Avere merger backed by $320M raisestocktitan.net · Jul 2026NextCure and Avere Merger Signals Ambitious Push Toward...marketchameleon.com · Jul 2026

Frequently asked questions

What does Nextcure do?
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
Who are Nextcure's investors?
Nextcure's investors include Canaan Partners, LAV, Lilly Asia Ventures, Pfizer Venture Investments, Quan Capital, Sofinnova Ventures, Taiho Ventures, LLC, OrbiMed.
How much funding has Nextcure raised?
Nextcure has disclosed $129.9M raised across 3 rounds.
Where is Nextcure headquartered?
Nextcure is headquartered in Beltsville, US.